Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RUN and FYVE domain-containing protein 2 (RUFY2) is a multidomain regulatory protein comprised of an N-terminal RUN domain, two central coiled-coil domains, and a C-terminal FYVE zinc finger domain. It is found predominantly in the cytoplasm and nucleus, where it regulates intracellular vesicle trafficking, endocytosis, and cytoskeletal network dynamics through interactions with small GTPases such as Rab33A, and potentially binds phosphatidylinositol-3-phosphate at endosomal membranes. RUFY2 participates in autophagy, is modulated by microRNAs (miR-155), and is frequently mutated in certain cancers, suggesting roles in cellular homeostasis, cancer, neurodegeneration, and immunity, although it is not yet established as a direct therapeutic target. The protein does not have transmembrane domains or signal peptides, but binds to partners via its RUN and FYVE domains and SH3-binding sites.
No specific mechanisms, as no therapeutics directly target RUFY2. Regulatory modulation may be indirect, e.g., via miR-155 influencing RUFY2 expression in immune processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RUN and FYVE domain-containing protein 2 (RUFY2).